FUKUSHIMA MEDICAL UNIVERSITY
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Private
- Established
- 1950-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.fmu.ac.jp
Clinical Trials
137
Active:0
Completed:87
Trial Phases
5 Phases
Phase 1:12
Phase 2:5
Phase 3:2
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (135 trials with phase data)• Click on a phase to view related trials
Not Applicable
115 (85.2%)Phase 1
12 (8.9%)Phase 2
5 (3.7%)Phase 3
2 (1.5%)Phase 4
1 (0.7%)Awareness and Knowledge of the Surgical Safety Checklist Among Operational Staff in University Teaching Hospital, Kathmandu, Nepal: A Cross-sectional Questionnaire
Completed
- Conditions
- Surgical Checklist
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- Fukushima Medical University
- Target Recruit Count
- 150
- Registration Number
- NCT04126889
- Locations
- 🇳🇵
Tribhuvan University Teaching Hospital, Kathmandu, Nepal
Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)
- First Posted Date
- 2018-03-05
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- Fukushima Medical University
- Target Recruit Count
- 41
- Registration Number
- NCT03453164
- Locations
- 🇯🇵
Fukushima Medical University Hospital, Fukushima, Japan
Retinal Sensitivity in BRVO After Anti-VEGF Therapy
Phase 4
- Conditions
- Branch Retinal Vein Occlusion
- Interventions
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Fukushima Medical University
- Target Recruit Count
- 50
- Registration Number
- NCT02527733
- Locations
- 🇯🇵
Department of Ophthalmology, Fukushima Medical University, Fukushima, Japan
HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1)
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2010-12-24
- Lead Sponsor
- Fukushima Medical University
- Target Recruit Count
- 6
- Registration Number
- NCT01266720
- Locations
- 🇯🇵
Fukushima Medical University Hospital, Fukushima, Japan
Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma
Phase 1
- Conditions
- Hepatocellular Carcinoma
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2010-12-24
- Lead Sponsor
- Fukushima Medical University
- Target Recruit Count
- 9
- Registration Number
- NCT01266707
- Locations
- 🇯🇵
Fukushima Medical University Hospital, Fukushima, Japan
- Prev
- 1
- 2
- Next
News
No news found